NCT06690840View on ClinicalTrials.gov

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 15, 2026

Study Completion Date

February 15, 2027

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Atezolizumab in combination with Cyclophosphamide and Vinorelbine

Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles

Trial Locations (5)

20141

European Institute of Oncology, Milan

20900

Fondazione IRCCS San Gerardo Dei Tintori, Monza

Unknown

Azienda Sanitaria Locale Br, Brindisi

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

All Listed Sponsors
lead

European Institute of Oncology

OTHER